Related Research Articles
Haemophilia, or hemophilia, is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. This results in people bleeding for a longer time after an injury, easy bruising, and an increased risk of bleeding inside joints or the brain. Those with a mild case of the disease may have symptoms only after an accident or during surgery. Bleeding into a joint can result in permanent damage while bleeding in the brain can result in long term headaches, seizures, or an altered level of consciousness.
Transfusion medicine is the branch of medicine that encompasses all aspects of the transfusion of blood and blood components including aspects related to hemovigilance. It includes issues of blood donation, immunohematology and other laboratory testing for transfusion-transmitted diseases, management and monitoring of clinical transfusion practices, patient blood management, therapeutic apheresis, stem cell collections, cellular therapy, and coagulation. Laboratory management and understanding of state and federal regulations related to blood products are also a large part of the field.
Blood plasma is a light amber-colored liquid component of blood in which blood cells are absent, but which contains proteins and other constituents of whole blood in suspension. It makes up about 55% of the body's total blood volume. It is the intravascular part of extracellular fluid. It is mostly water, and contains important dissolved proteins, glucose, clotting factors, electrolytes, hormones, carbon dioxide, and oxygen. It plays a vital role in an intravascular osmotic effect that keeps electrolyte concentration balanced and protects the body from infection and other blood-related disorders.
Canadian Blood Services is a non-profit charitable organization that is independent from the Canadian government. The Canadian Blood Services was established as Canada's blood authority in all provinces and territories except for Quebec in 1998. The federal, provincial and territorial governments created the Canadian Blood Services through a memorandum of understanding. Canadian Blood Services is funded mainly through the provincial and territorial governments.
Fresh frozen plasma (FFP) is a blood product made from the liquid portion of whole blood. It is used to treat conditions in which there are low blood clotting factors or low levels of other blood proteins. It may also be used as the replacement fluid in plasma exchange. Using ABO compatible plasma, while not required, may be recommended. Use as a volume expander is not recommended. It is administered by slow injection into a vein.
In England, blood and other tissues are collected by NHS Blood and Transplant (NHSBT). NHSBT Blood Donation was previously known as the National Blood Service until it merged with UK Transplant in 2005 to form a NHS special health authority. Other official blood services in the United Kingdom include the Northern Ireland Blood Transfusion Service, the Scottish National Blood Transfusion Service and the Welsh Blood Service.
Thomas Addis Jr. was a Scottish physician-scientist from Edinburgh who made important contributions to the understanding of how blood clots work. He was a pioneer in the field of nephrology, the branch of internal medicine that deals with diseases of the kidney. Addis described the pathogenesis of haemophilia in 1911 and was the first to demonstrate that normal plasma could correct the defect in haemophilia.
NHS Blood and Transplant is an executive special health authority of the United Kingdom's Department of Health and Social Care. It was established on 1 October 2005 to take over the responsibilities of two separate NHS agencies: UK Transplant, founded by Dr. Geoffrey Tovey in 1972, and the National Blood Service. Its remit is to provide a reliable, efficient supply of blood, organs and associated services to the NHS. Since NHSBT was established, the organisation has maintained or improved the quality of the services delivered to patients, stabilised the rising cost of blood, and centralised a number of corporate services.
Factor 8: The Arkansas Prison Blood Scandal is a feature-length documentary by Arkansas filmmaker and investigative journalist, Kelly Duda, released in 2005. Through interviews and the presentation of documents and footage, Duda alleged that in the 1970s and 1980s, the Arkansas prison system profited from selling blood plasma from inmates infected with viral hepatitis and HIV. The documentary contends that thousands of victims who received transfusions of blood products derived from these plasma products, Factor VIII, died as a result.
The Lister Institute of Preventive Medicine, informally known as the Lister Institute, was established as a research institute in 1891, with bacteriologist Marc Armand Ruffer as its first director, using a grant of £250,000 from Edward Cecil Guinness of the Guinness family. It had premises in Chelsea in London, Sudbury in Suffolk, and Elstree in Hertfordshire, England. It was the first medical research charity in the United Kingdom. It was renamed the Jenner Institute in 1898 and then, in 1903, as the Lister Institute in honour of the great surgeon and medical pioneer, Dr Joseph Lister. In 1905, the institute became a school of the University of London.
The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a Directorate and partial agreement of the Council of Europe that traces its origins and statutes to the Convention on the Elaboration of a European Pharmacopoeia.
The New Zealand Blood Service is the provider of blood services for New Zealand. The service is a Crown entity responsible to New Zealand's Parliament and is governed by a Board appointed by the Minister of Health.
The contaminated blood scandal, also known as the infected blood scandal, is a British medical scandal in which a large number of people were infected with hepatitis C and HIV, as a result of receiving contaminated blood or contaminated clotting factor products. Many of the products were imported from the US, and distributed to patients by the National Health Service throughout the 1970s and 1980s. Most recipients had haemophilia or had received a blood transfusion following childbirth or surgery. It has been estimated that more than 30,000 patients received contaminated blood, resulting in the deaths of at least 3,000 people. In July 2017, Prime Minister Theresa May announced an independent public inquiry into the scandal, for which she was widely praised as successive governments going back to the 1980s had refused such an inquiry. May stated that "the victims and their families who have suffered so much pain and hardship deserve answers as to how this could possibly have happened." The final report was published in seven volumes on 20 May 2024, concluding that the scandal could have been largely avoided, patients were knowingly exposed to "unacceptable risks", and that doctors, the government and NHS tried to cover up what happened by "hiding the truth".
Professor Ralph Ambrose Kekwick. was a British biochemist who did pioneering work on human plasma fractionation, including the first production of Factor VIII.
The Welsh Blood Service is a division of Velindre University NHS Trust responsible for the collection of blood in Wales, and of the distribution of blood products to hospitals within the country, as well as other related functions.
Fereydoun Ala is an Iranian physician and academician, specialised in internal medicine, haematology, blood transfusion and haemostasis, who established the first Clinical Haematology Department, and the first Haemophilia Centre in Iran at the Tehran University Medical Faculty. He was the founder of the Iranian National Blood Transfusion Service (INBTS), a centralised, state-funded organisation, established in 1974, for the recruitment of healthy, voluntary, non-remunerated blood donors.
The Creat Group is a Chinese investment firm based in Beijing incorporated in 1992. It has expertise in the plasma industry and invests in healthcare and pharmaceuticals, manufacturing, energy, finance, natural resources, and real estate.
A and Others v National Blood Authority and Another, also known as the Hepatitis C Litigation, was a landmark product liability case of 2001 primarily concerning blood transfusions but also blood products or transplanted organs, all of which were infected with hepatitis C, where liability was established under the Consumer Protection Act 1987 and the Product Liability Directive (85/374/EEC) even in the absence of the ability to test to ascertain which blood transfusions were defective. The claimants were 114 individuals, six of whom were considered lead plaintiffs and given close consideration by the judge, Mr Justice Burton. Several of the claimants were minors who had become infected with Hepatitis C in the course of their treatment for leukaemia. The defendants were the National Blood Authority (NBA) and in respect of Wales, the Velindre NHS Trust, Cardiff. The court found that the UK government should have implemented measures to screen donated blood for HCV by March 1990, rather than September 1991, and that surrogate testing should have been introduced within the United Kingdom no later than 1 March 1988.
The Iranian Blood Transfusion Organization or acronymly IBTO is the highest and only decision-making authority in the field of supply and distribution of healthy blood and blood products in Iran. This organization was established in July 31, 1974.
The HIV Haemophilia Litigation [1990] 41 BMLR 171, [1990] 140 NLJR 1349 (CA), [1989] E N. 2111, also known as AMcG002, and HHL, was a legal claim by 962 plaintiffs, mainly haemophiliacs, who were infected with HIV as a result of having been treated with blood products in the late 1970s and early 1980s. The first central defendants were the then Department of Health, with other defendants being the Licensing Authority of the time, (MCA), the CSM, the CBLA, and the regional health authorities of England and Wales. In total, there were 220 defendants in the action.
References
- ↑ "Bio Products Laboratory Limited overview – Find and update company information – GOV.UK". Companies House . 11 August 2010. Retrieved 15 February 2024.
- ↑ "About BPL". Bio Products Laboratory. Archived from the original on 29 October 2015. Retrieved 21 October 2015.[ self-published source ]
- ↑ "Permira Funds and the Marcucci family complete investment in Kedrion and BPL and announce appointment of Ugo Di Francesco as CEO". Permira. Retrieved 29 December 2022.
- ↑ "Final Report: Chapter 19 – Production of Blood Products – Facilities". penroseinquiry.org.uk.
- ↑ Wheeler, Caroline (23 August 2015). "Sick children infected with HIV and used as guinea pigs as NHS said chimps 'too expensive'". Express.co.uk.
- ↑ Staff (17 December 2002). "UK buys 'safe' blood supply for NHS". BBC News World Edition. Retrieved 21 October 2015.
- ↑ "Transfer of Bio Products Laboratory to Limited Co". Bio Products Laboratory. 5 January 2011. Archived from the original on 8 August 2011.[ self-published source ]
- ↑ "Bain Capital buys stake in UK government blood company". BBC News. 19 July 2013. Archived from the original on 19 July 2013. Retrieved 13 November 2020.
- ↑ "Bain Capital buys majority stake in Plasma Resources UK". The Guardian. 18 July 2013. Archived from the original on 30 July 2013. Retrieved 13 November 2020.
- ↑ "Permira Funds and the Marcucci family complete investment in Kedrion & BPL". Kedrion. Retrieved 29 December 2022.
